SEOUL, South Korea, April 3, 2026 /PRNewswire/ — Upbit, a world-class digital asset exchange operated by Dunamu Inc., today announced that it has signed a Memorandum of Understanding (MOU) with Indonesia Crypto Exchange (ICEx), a licensed digital asset bourse in Indonesia. The MOU establishes a strategic framework for technical and operational collaboration aimed at accelerating the development of Indonesia’s regulated crypto ecosystem and supporting the growth of a sustainable, well-governed market.

The partnership was marked by a high-level summit held at Upbit’s Seoul headquarters, where CEO Kyoungsuk Oh hosted a senior Indonesian delegation comprising high-ranking government officials, representatives from the Chamber of Commerce Indonesia, and key industry players to discuss the evolution of regulated digital finance.

The inclusion of the Chamber of Commerce underscores the mission to integrate it into the broader Indonesian commercial landscape. During the meetings, Upbit’s leadership and Kadin representatives discussed future-forward plans to bridge Korean technological prowess with Indonesian market potential, ensuring that the digital asset roadmap aligns with the country’s national economic interests and private sector growth.

Building a Regulated Global Standard

Under this strategic framework, Upbit will support the growth of Indonesia’s digital asset ecosystem by providing core platform technology and operational expertise to build and operate a resilient, compliant trading venue, including key exchange infrastructure such as matching, risk management, and market operations.

The partnership will also explore innovation in areas such as custody solutions while strengthening regulatory technology to enhance oversight, compliance, and reporting. 

ICEx and Upbit have aligned as strategic partners to leverage Upbit’s proven track record as South Korea’s leading exchange and its global reputation for maintaining the highest standards in investor protection and regulatory compliance.

Expanding Upbit’s Regional Footprint

Upbit is positioning itself as a critical infrastructure partner across Asia, supporting the development of secure, transparent, and trusted digital asset market frameworks.

This collaboration marks another milestone in Upbit’s expanding role as a key driver of digital asset development across the region. The company has previously hosted high-level delegations from Vietnam—including senior government and financial leaders such as the Minister of National Defense, Minister of Finance, Chairperson of the State Securities Commission, and the Chairman of Military Bank—to showcase its advanced digital asset exchange infrastructure.

“This partnership reflects our commitment to fostering well-regulated digital asset ecosystems globally,” said Kyoungsuk Oh, CEO of Dunamu, operator of Upbit. “By working closely with ICEx, we aim to share the platform technology and operational expertise that have established Upbit as a market leader in Asia and strengthen the foundational infrastructure of Indonesia’s digital asset sector.”

A New Era for Indonesian Digital Finance

ICEx operates as an important part of Indonesia’s regulated digital asset ecosystem under the supervision of the Financial Services Authority (OJK). Established in line with Indonesia’s three-layer regulatory framework for digital asset transactions, comprising a licensed bourse, central clearinghouse, and supporting an integrated market structure within the country’s regulated framework. Upbit Indonesia is among its founding shareholders, alongside strategic investors including some of Indonesia’s largest conglomerates and global exchanges.

 “Partnering with Upbit brings invaluable global expertise to our local ecosystem,” said Pang Xue Kai, CEO of ICEx Group. “Upbit’s leadership in compliance and technology was a decisive factor for us. We believe this collaboration will contribute to the development of a more secure and trusted market environment in Indonesia.”

Through this partnership, Upbit aims to support ICEx in laying the groundwork for a next-generation digital asset ecosystem in Indonesia while contributing to the broader evolution of regulated crypto markets across the region.

The parties formally announced the MOU at the Korea–Indonesia Business Partnership for Resilient Growth Forum on April 1st, 2026, a landmark bilateral event, attended by ministers and high-ranking officials from both countries. The forum featured the signing of MOUs by major companies from both countries across a range of sectors. The MOU between Upbit and ICEx underscored the strategic and institutional significance of the bilateral collaboration in digital finance innovation.

About Upbit

Upbit is a leading digital asset exchange headquartered in South Korea and operated by Dunamu Inc., a fintech company focused on building innovative financial services powered by blockchain technology. Since its launch in 2017, Upbit has become one of the largest cryptocurrency exchanges globally by trading volume, offering a wide range of digital assets and trading pairs.

Upbit provides a secure and user-friendly platform for trading, investing, and managing digital assets. The company prioritizes transparency, compliance, and investor protection, adopting industry-leading security practices.

Through continuous innovation and strategic partnerships, Upbit aims to drive the adoption of blockchain technology and contribute to a more accessible and efficient financial ecosystem.

BANGKOK, April 3, 2026 /PRNewswire/ — WHX Bangkok 2026 organised by Informa Markets is set to be a landmark trade event for showcasing Korea’s groundbreaking advancements in AI-driven healthcare and technology. Two leading Korean companies, Korea Body Information Co., Ltd. and maihub, will unveil their flagship solutions at the trade show taking place from 8 – 10 July 2026 at Queen Sirikit National Convention Centre (QSNCC) in Bangkok.

Real PT: Revolutionising Musculoskeletal Healthcare

Korea Body Information Co., Ltd. will debut its flagship solution, Real PT, an AI-powered musculoskeletal diagnostic and exercise prescription system. Real PT is an integrated digital healthcare platform that combines posture assessment, range of motion (ROM) testing, functional musculoskeletal evaluation, and personalised exercise prescription into a single, user-friendly system. Designed for hospitals, clinics, rehabilitation centres, and wellness facilities, Real PT offers:

• AI-based posture analysis with 99.3% diagnostic accuracy for non-contact assessments in just 40 seconds.
• Portable design requiring only 2.2 meters of space, wheelchair accessibility, and visualised reports for seamless progress tracking.
• Proven success with over 2.8 million users across 500+ facilities in Korea, including hospitals, public health centres, and fitness centres.

Real PT’s debut at WHX Bangkok marks Korea Body Information’s first official entry into the Thai medical device market. With Thailand’s growing demand for rehabilitation and preventive healthcare solutions, Real PT is uniquely positioned to meet these needs. Live demonstrations at the Korea Body Information booth will showcase its real-world applications in medical and rehabilitation settings.

“The future of healthcare is not only about diagnosis—it is about continuous management. Through AI-based musculoskeletal diagnosis and personalised exercise prescription, we aim to present a new paradigm that connects assessment with long-term care. Our participation at WHX Bangkok 2026 is a key milestone in our strategy to expand into the Thai market,” said Jae-hoon Jeong, CEO of Korea Body Information Co., Ltd

maihub: Easy way to meet AI

maihub, another leading innovator from Korea, will present maiLink and maiReport. maihub is a Korea-based company developing a medical AI orchestration platform designed to make AI more accessible and practical in clinical settings — under the slogan “Easy way to meet AI.” maiLink is already deployed across more than 1,300 medical institutions worldwide. With regulatory approvals from the U.S. FDA 510(k), Malaysia’s MDA, and Indonesia’s BPOM, the company is expanding into global markets.

maiLink — the medical AI orchestration platform optimised for the diverse network environments across Southeast Asia. Designed to minimise changes to existing hospital IT infrastructure, it enables stable AI operation and allows local hospitals to adopt AI immediately — without significant upfront investment. Its hybrid architecture keeps patient data processed and managed on-site, while anonymization and encryption ensure compliance with data protection regulations and cybersecurity requirements across the region.

maiReport, an approach that extends medical AI beyond clinicians to patients. AI analysis results — previously accessible only to medical staff — can now be delivered directly to patients through automated reports and a mobile app, maiReport. This allows hospitals to differentiate their services while enabling patients to take a more active role in managing their own health.

“WHX Bangkok 2026 is the perfect opportunity for us to showcase our solutions to Thailand and the regional market,” said Hyuck Yang, CEO of maihub. “Southeast Asia is a market where the impact of medical AI can be most profound, precisely because healthcare infrastructure has not kept pace with demand. Through a platform that connects medical AI in a truly usable form, we aim to become the core infrastructure that enhances clinical efficiency and helps bridge the gap in healthcare access across the region.”

Korea’s Strategic Market Entry at WHX Bangkok 2026

Korea’s AI-driven solutions exemplify the future of healthcare innovation. Their debut at WHX Bangkok 2026 highlights Korea’s leadership in leveraging artificial intelligence to improve diagnostics, treatment, and patient care. Visitors to the event will have the unique opportunity to experience these transformative technologies firsthand, setting the stage for a new era in healthcare.

About WHX Bangkok 2026
World Health Expo (WHX) Bangkok (formerly Medlab Asia and Asia Health), is an exhibition that covers medical devices, medical laboratories, hospital services and healthcare system. The trade event will take place from 8 – 10 July 2026 at Queen Sirikit Convention Centre (QSNCC) in Bangkok. Attendee registration for the event is now live. For more information visit https://www.worldhealthexpo.com/events/healthcare/bangkok/en/home.html.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.

For Media enquiries, please contact:
Gautam Jatwani
Senior Marketing Manager
Informa Markets
Gautam.jatwani@informa.com

RIVERSIDE, Calif., April 3, 2026 /PRNewswire/ — PartnerOne, one of the fastest-growing enterprise software groups worldwide, is proud to announce the official close of its acquisition of Mortgage Cadence, a leading provider of cloud-based digital lending solutions.

With the completion of this strategic acquisition, Mortgage Cadence joins the PartnerOne portfolio, gaining a long-term platform for growth, innovation, and customer-centric excellence. The integration will accelerate Mortgage Cadence’s ability to transform the mortgage origination experience for lenders and borrowers, streamlining loan origination, reducing operational costs, and enhancing borrower experiences through AI, robust automation and new capabilities.

This marks a significant milestone in the evolution of Mortgage Cadence and further solidifies PartnerOne’s position as a global leader in enterprise software.

“Welcoming Mortgage Cadence into the PartnerOne family marks a pivotal moment for both organizations,” said Suzanne Fortman, Vice President at PartnerOne. “We are committed to empowering Mortgage Cadence’s talented team, supporting their innovation, and expanding the resources needed to serve customers and partners at the highest level. Together, we look forward to shaping the future of digital mortgage technology.”

PartnerOne is committed to ensuring stability and a seamless transition for Mortgage Cadence’s customers and partners. Continuing its tradition of investing in enduring software companies, PartnerOne will provide Mortgage Cadence with the resources and operational excellence needed to evolve its platform and deepen customer relationships.

About PartnerOne

PartnerOne is one of the fastest growing enterprise software groups in the world, with a proven track record of acquiring and growing enterprise software companies. Over 2000 enterprises and government organizations rely on PartnerOne software, including 80% of the largest companies in the world. With an “Acquire. Invest. Grow.” philosophy, PartnerOne provides a “forever-home” for acquired businesses and helps them thrive with shared resources and sustained investment. For more information, visit www.partnerone.com.

About Mortgage Cadence

Mortgage Cadence delivers the industry’s most complete, modern, cloud-based digital lending platform designed to provide an exceptional user experience throughout the entire mortgage lending life cycle, across all channels and products. With leading borrower point-of-sale through closing collaboration tools, the end-to-end platform is both complete and configurable, offering an open architecture designed to meet the needs of today’s lenders. For more information, visit www.mortgagecadence.com. 

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data

Collaboration will expand Regeneron’s world-leading genomic and proteomic EHR-linked database

Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providers

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ — TriNetX^® and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a strategic collaboration to support Regeneron’s capabilities in drug discovery and development, as well as new initiatives to deliver digital health solutions of the future for consumers, patients and providers. Regeneron gains the exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading phenotypic data network of approximately 300 million de-identified and anonymized patients. This collaboration will enable expansion of Regeneron’s world-leading genomic and proteomic Electronic Health Record (EHR)-linked database, a key driver of the company’s industry-leading therapeutics pipeline.

Under the collaboration, TriNetX will provide Regeneron with secure, licensed access to TriNetX’s current and future de-identified health data from approximately 300 million individuals (170 million of whom are in the United States), sourced directly from its global network of health system partners. With privacy-preserving methods, Regeneron will have the capability to match a portion of TriNetX’s de-identified/anonymized data to genomic and proteomic data generated by the Regeneron Genetics Center^® (RGC^®). Such matching will be conducted in accordance with all applicable data privacy laws, including HIPAA and GDPR.

The RGC has developed high-throughput and cost-efficient DNA sequencing and proteomics approaches to build the world’s largest database of EHR-linked sequencing and proteomics data, in collaboration with over 150 life sciences and healthcare collaborators around the world. The collaboration with TriNetX will help Regeneron dramatically expand this already world-leading dataset to continue to drive drug discovery and development, while also empowering artificial intelligence (AI) training algorithms to deliver digital health solutions of the future.

“We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data,” said Jeff Margolis, TriNetX Executive Chairman. “Our team is gratified to be selected by Regeneron to provide access to TriNetX’s unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centers and other leading healthcare research sites.”

“This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world’s largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers,” said Aris Baras, M.D., Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines. “TriNetX has built a world-leading platform with a proven track record of enabling research at scale. The RGC has spent over a decade generating genomic and now proteomic data and integrating these molecular data with longitudinal health records at large-scale. Combining these platforms brings together powerful human health databases with analytical and AI capabilities to help discover and develop innovative medicines for devastating diseases and create digital health solutions that we hope will transform our ability to predict, prevent and manage disease.”

“We are looking forward to working with the TriNetX team,” said Andrew Deubler, Senior Vice President, RGC Chief Business and Administrative Officer. “Our RGC strategic investments catalyze innovation, driving advancements in cutting-edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions. This deal represents the latest and one of our most significant collaborations, and we look forward to continuing to expand our network of top-tier partners as we pursue our mission.”

As part of the collaboration, Regeneron will invest up to $200 million in TriNetX.

About TriNetX, LLC 
TriNetX is the Global Truth Engine for Better Human Health™ that makes complex, real-world health data easy to use. Data is sourced directly from our growing global network of over 11,000 healthcare provider locations. TriNetX customers select the data source, types, and breadth of data they need; the data access methods they desire; and the types of software, human and machine intelligence they wish to apply – and combine these to solve their business objectives. Visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn to learn more.

About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite^®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center^® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook, YouTube or X.

About the Regeneron Genetics Center
The Regeneron Genetics Center^® (RGC^®) is a genomic research initiative and a wholly owned subsidiary of Regeneron. For over a decade, we have harnessed the power of human genetics to discover important new medicines, validate existing research programs and optimize clinical trials. We tap into our growing database of more than 3 million sequenced exomes and de-identified health information using proprietary data analytics, technology and human ingenuity to make meaningful biological discoveries at speed and scale. Our high-touch integrated model focuses on working closely with our collaborators to build a dataset with meaningful cohorts. We use innovative technologies, such as machine learning, to sequence exomes, align with health information and perform large-scale analyses to make meaningful associations between genes and diseases. We apply our insights to guide Regeneron’s broader drug discovery and development efforts.

Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”), research and clinical programs now underway or planned, and the use of human genetics in Regeneron’s research programs; the likelihood, timing, and scope of achieving any of the anticipated milestones described in this press release; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (such as those that may result from Regeneron’s collaboration with TriNetX discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates and new indications for Regeneron’s Products; uncertainty of the utilization, market acceptance, and commercial success of Regeneron’s Products and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on any of the foregoing; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) as well as the collaboration with TriNetX discussed in this press release, to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron’s business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA^® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Regeneron
Media:
Ella Campbell
Email: ella.campbell@regeneron.com

Investors:
Vesna Tosic
Email: vesna.tosic@regeneron.com

TriNetX
Karen Tunks
Email: Karen.Tunks@TriNetX.com

Transaction unites Canadian and U.S. culinary institutions under Triumph portfolio

SCHAUMBURG, Ill. and VANCOUVER, BC, April 3, 2026 /PRNewswire/ — Triumph Higher Education Group today announced it acquired PICA Holdings Incorporated, the parent company of the Pacific Institute of Culinary Arts (PICA), a Vancouver-based institution for professional culinary and pastry arts education, effective April 1.

The acquisition brings PICA into Triumph’s culinary education portfolio alongside Auguste Escoffier School of Culinary Arts (Escoffier), the largest culinary school brand in the United States,* expanding its network of accredited, career-focused culinary institutions across North America. Financial terms were not disclosed.

In addition to its business-focused curriculum that includes entrepreneurship and wellness programs, Triumph said the acquisition aligns with its strategy to further expand professional education programs in high-demand sectors including hospitality and culinary arts to address employers’ skilled labor shortages. Both PICA and Escoffier blend traditional methods with modern innovation representing a foundation that has shaped current culinary arts across North America and globally. This shared philosophy and approach underscores the alignment between the two institutions.

“We are pleased to welcome the students, faculty and partners of PICA to the Triumph family,” said Jack Larson, chairman, CEO and president of Triumph Higher Education Group. “PICA’s approach to culinary education, rooted in excellence, tradition and innovation, aligns with our strategy to expand career-focused programs in hospitality and culinary fields, where demand for skilled professionals continues to grow.”

“PICA has earned a strong reputation for developing industry-ready graduates through disciplined, hands-on training and deep employer connections,” said Kirk T. Bachmann, provost at Escoffier. “Our missions share a commitment to cultivating passion and lifelong careers in the culinary and hospitality professions. Bringing PICA into the Triumph family allows us to expand opportunities for students while strengthening the culinary talent pipeline across North America and internationally.”

Founded in 1997 in Vancouver, British Columbia, PICA offers intensive diploma programs in culinary and baking and pastry arts, with a training model centered on hands-on instruction, small class sizes and direct industry engagement. The institution is accredited in British Columbia and prepares students for careers in restaurants, hotels, bakeries and food-related businesses. The institution has also participated in industry events tied to Vancouver’s growing international culinary profile.

PICA will continue operating from its Vancouver campus, with no disruption expected for current students or programs. Former owners Yves and Sylvia Potvin will continue in an active advisory role following the acquisition. The institution will maintain its hands-on instructional model and local industry relationships. PICA will operate within Triumph’s culinary division, alongside Auguste Escoffier School of Culinary Arts. Triumph will continue to invest in the PICA campus, facility, and community.

Students at both institutions will have access to expanded academic resources, broader employer partnerships, international experiences and cross-border career pathways. The combined programs will support the education and development of future culinary and hospitality leaders.

“Joining Triumph marks an important step forward for PICA,” said Yves Potvin, of Pacific Institute of Culinary Arts. “We are proud of our role in Vancouver’s culinary community and look forward to expanding opportunities for our students, alumni and instructors while continuing to serve Western Canada and our international student population.”

PICA has trained more than 4,500 alumni since its founding, with graduates working across restaurants, hotels and hospitality businesses throughout North America and internationally.

The acquisition expands Triumph’s culinary education and workforce development capabilities through its existing operations, including Auguste Escoffier School of Culinary Arts. Escoffier offers accredited degree and diploma programs through campuses in Boulder, Colorado, and Austin, Texas, as well as online. Auguste Escoffier Global Solutions provides hiring, training and retention support for hospitality employers.

Together, Triumph’s network will serve approximately 8,000 students annually, with an alumni network of more than 25,000 and over 125 faculty and chef instructors across North America.

About Triumph Higher Education Group
Triumph Higher Education Group is a global provider of education, training and recruitment of professionals for the hospitality and culinary arts industries. Its operations include Auguste Escoffier School of Culinary Arts, Gecko Hospitality, Auguste Escoffier Global Solutions and Pacific Institute of Culinary Arts.

About Pacific Institute of Culinary Arts
Pacific Institute of Culinary Arts, Canada’s oldest, private culinary school, was founded in 1997 and is located at the entrance of Granville Island, one of Vancouver’s most iconic tourism and hospitality destinations. Consistently ranked as one of Canada’s best culinary training centers, the institute’s offerings range from professional diploma programs in the culinary and baking and pastry arts to wine education and cooking classes for the public. An onsite bakery and marina-side bistro event space ensures that there is something for every kind of culinary enthusiast. Committed to excellence, Pacific Institute of Culinary Arts’ mission is to provide the highest quality culinary and hospitality education for all.

About Auguste Escoffier School of Culinary Arts
Auguste Escoffier School of Culinary Arts is the largest culinary school brand in the U.S.*, with a community of thousands of alumni represented across the United States and internationally. Escoffier’s programs blend a classic and contemporary approach to culinary and pastry arts, emphasizing sustainability, farm-to-table practices, business skills, and food entrepreneurship. The Austin, Texas, campus is nationally accredited by the Council on Occupational Education (COE), and the Boulder, Colorado, campus (including online programs) is nationally accredited by the Accrediting Council for Continuing Education and Training (ACCET). Escoffier is ranked one of the Best Colleges for Culinary Arts in America 2026 by Niche.com. Both the Boulder and Austin campuses are Great Place to Work-Certified™ institutions. Escoffier’s Boulder campus (including online programs) has also been recognized as a Military Friendly® School and by Newsweek as a Top Online Learning Provider for 2026.

*Auguste Escoffier School of Culinary Arts is the largest culinary school brand in the U.S. (based on comparable student population data currently reported in IPEDS).

Private Equity Partner Shamrock Capital Fuels Strategic Market Expansion

ATLANTA, April 3, 2026 /PRNewswire/ — Nth Degree, a leader in event design and delivery, today announced that global brand storytelling agency INVNT will join the organization, creating a live event market leader capable of meeting the growing experiential needs of major brands around the world. With 11 offices across Europe, the Middle East, Asia-Pacific, and North America, INVNT brings expanded creative, strategy and production capabilities to the combined company.

“We’re excited to welcome INVNT and their entire team to the Nth Degree family,” said John Hense, CEO of Nth Degree. “As the market for experiential services continues to accelerate, we’re bringing together the exceptional creative talent and leadership of INVNT with Nth Degree’s proven team, strengthening an already formidable platform company – one that will help global brands tell bigger stories and deliver them with more confidence than ever before.”

As part of this transaction, Nth Degree Events – the award-winning division of the parent company – and INVNT will combine to form an agency focused on corporate events operating under the brand name INVNT.

“Clients today are increasingly seeking integrated agency partners that can deliver high-touch service and accountability all the way from strategy and creative to production and operations,” said Kristina McCoobery, Global President of INVNT. “Adding the capabilities of Nth Degree Events to INVNT’s suite allows us to address that need.”

The integration of INVNT and Nth Degree Events creates significant advantages and a more competitive, comprehensive suite of offerings for clients, giving them access to innovation-led brand storytelling, creative, strategy and production expertise along with revenue-enhancing sponsorship sales, content and speaker management, best-in-class event operations and more.

“Nth Degree Events clients have been increasingly seeking the kind of services that INVNT delivers, and we’re excited to bring these capabilities to our exceptional customer base including some of the biggest names in consumer and technology markets,” said Robert Lowe, Chief Client Officer, of the newly combined agency.

The business will operate through two primary divisions under the leadership of John Hense, CEO of Nth Degree Holdings:

INVNT – Nth Degree Events merges with INVNT creating a strengthened suite of agency services and a combined client base that includes some of the largest and best-known brands in the world – from consumer to business-to-business. INVNT co-founder McCoobery, along with members of the Nth Degree Events team, including Lowe and Lisa Ramsey, will lead the agency.  

Nth Degree – With a focus on high-quality event labor and general contracting services, Nth Degree and Fern Exposition Services maintain the company’s longstanding commitment to exhibitors, exhibit houses, associations and agencies. Nth Degree will be led by Russell Greenway, President, Nth Degree – I&D, and Shana Carr, President, Fern Expo – GC.

The deal was supported by private equity partner Shamrock Capital and represents a significant expansion of Shamrock’s commitment to the experiential market while bolstering Nth Degree’s continued growth and global expansion. Shamrock announced its initial strategic investment in Nth Degree in September 2024.

Canaccord Genuity served as exclusive financial advisor and Davis + Gilbert LLP served as legal advisor to INVNT on the transaction. Willkie Farr & Gallagher LLP served as legal advisor and Stephens Inc. served as financial advisor to Nth Degree on the transaction.

About Nth Degree
Nth Degree is a global leader in exhibitor and trade show services, event management, experiential marketing, and permanent installations. With warehouses and offices in more than 30 U.S. markets, the company delivers thousands of events annually for many of the world’s most recognizable brands. For more information visit nthdegree.com.

About INVNT
On a mission to put a brand on the moon. INVNT® is an innovation-led, international, interdisciplinary, and integrated agency united by brand storytelling. INVNT helps many of the biggest brands and organizations in the world impact audiences, dent culture, and make history. INVNT operates globally with offices in New York (HQ), London, Sydney, Singapore, Mumbai, Dubai, Detroit, San Francisco, Stockholm, Noosa, and Washington D.C. For more information visit INVNT.com.

About Shamrock Capital
Shamrock Capital is a Los Angeles-based investment firm with approximately $7 billion of assets under management as of February 13, 2026. Shamrock Capital invests exclusively in media, entertainment, communications, and related sectors through a multi-fund strategy centered on private equity investments, as well as ownership and financing of content and media rights. The firm was originally founded in 1978 as the family investment company for the late Roy E. Disney and has since evolved into an institutionally backed firm with a leading group of investors, including endowments, foundations, and sovereign wealth and pension funds. Shamrock Capital partners with strong management teams and takes an active, collaborative approach to creating value in each investment. For more information, visit shamrockcap.com.

Media Contacts:

Robyn Fernsworth
R2PR for Nth Degree
robyn@r2pr.com

Matt Keowen
Nth Degree
mkeowen@nthdegree.com

Jhonathan Mendez De Leon
INVNT
jmendezdeleon@invnt.com

ATLANTA, April 3, 2026 /PRNewswire/ — Precision Aviation Group (PAG), a leading global provider of aftermarket aviation and aerospace services, today announced that EFIX and PAG Australia have been added to the Safran Electrical & Power Authorized Repair Center (ARC) Network, further expanding PAG’s global OEM authorized repair capabilities.

PAG employee holds an aircraft part

With the addition of EFIX and PAG Australia, PAG now operates five Authorized Repair Centers within the Safran Electrical & Power ARC Network for its DC Generators and GCU, reinforcing the company’s commitment to providing high-quality, OEM-approved MRO support across key global regions.

The five PAG companies authorized within the Safran Electrical & Power ARC Network include:

• Precision Aviation Group (PAG) – Atlanta, Georgia, USA
• PAI Canada – British Columbia, Canada
• Tuner Aviation – Glasgow, Scotland
• EFIX – Brazil
• PAI Australia – Queensland, Australia

“This expansion reflects the continued investment we’re making across our Component Services organization to meet OEM standards while supporting customers where they operate,” said Jordan Webber, Vice President of Component Services at Precision Aviation Group. “Adding EFIX and PAG Australia to the Safran Electrical & Power ARC Network allows us to extend trusted, authorized repair and distribution capabilities into new regions while maintaining the quality, consistency, and reliability our customers expect.”

Safran Electrical & Power is a global leader in aircraft electrical systems, and its Authorized Repair Center Network is designed to ensure consistent standards of quality, compliance, and performance across approved service providers.

The inclusion of EFIX and PAG Australia enables PAG to offer expanded regional coverage in South America and the Asia-Pacific region, reducing turnaround times while maintaining the highest standards of safety and reliability.

About Precision Aviation Group (PAG)
Precision Aviation Group (PAG) is a leading provider of maintenance, repair, and overhaul (MRO) and value-added supply chain services to the aerospace and defense industries. With 26 Repair Stations, 28 locations worldwide, 1,280 employees, and over 1.2 million square feet of production and distribution facilities, PAG offers comprehensive MRO services on more than 200,000 product lines. PAG supports operators in the Airline, Business and General Aviation (BGA), Military, and Rotary Wing markets through its Inventory Supported Maintenance, Repair, and Overhaul (ISMRO^®) business model.
www.precisionaviationgroup.com

About Safran
Safran is an international high-technology group, operating in the aviation (propulsion, equipment and interiors), defense and space markets. Its core purpose is to contribute to a safer, more sustainable world, where air transport is more environmentally friendly, comfortable and accessible. Safran has a global presence, with 100,000 employees and sales of 27.3 billion euros in 2024, and holds, alone or in partnership, world or regional leadership positions in its core markets. Safran is listed on the Euronext Paris stock exchange and is part of the CAC 40 and Euro Stoxx 50 indices.

Safran Electrical & Power is one of the world’s leaders in aircraft electrical systems. The company is a key player in equipment electrification and in the electric and hybrid propulsion sector. It has more than 15,500 employees across 13 different countries.

For more information: www.safran-group.com

Photo – https://laotiantimes.com/wp-content/uploads/2026/04/precision_aviation_group__pag_employee_holds_an_aircraft_part.jpg 

Logo – https://laotiantimes.com/wp-content/uploads/2026/04/precision_aviation_group_logo.jpg